文献速递介入腹部US

DNA修复抑制剂DT01在临床前模型中增强多柔比星对肝细胞癌的疗效

Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models.
PubMed 文献 · Eur Radiol · 2017-04-03

在兔肝肿瘤模型和小鼠人肝细胞癌模型中,DNA修复抑制剂DT01联合TACE或多柔比星可显著抑制肿瘤生长并减少血管化,且耐受良好;DT01可能通过增强DNA损伤和抗血管生成作用提高肝细胞癌疗效。

要点

  • DT01联合TACE在兔肝肿瘤模型中显著减小肿瘤体积(p=0.03)。
  • 彩色多普勒和免疫组化显示DT01+TACE组血管化明显减少,阻止了单用TACE后的肿瘤再生长。
  • DT01联合多柔比星在小鼠人肝细胞癌模型中较单用多柔比星显著抗肿瘤(p=0.02)。

核心结论

  • DT01耐受良好,可能通过增强TACE与多柔比星的DNA损伤和抗血管化效应来增强肝细胞癌治疗效果。

研究设计与样本

  • 临床前研究:兔肝肿瘤模型分为未治疗、TACE、TACE+DT01三组,超声监测肿瘤生长;小鼠肝内人肝细胞癌模型分别接受多柔比星单药或多柔比星+DT01治疗以验证结果。

关键影像表现/征象

  • 彩色多普勒和免疫组化染色显示DT01+TACE治疗组血管化强烈减少,阻止了单用TACE后观察到的肿瘤再生长。
  • 在兔肝肿瘤模型中,DT01联合TACE导致肿瘤体积显著减小(p=0.03)。
  • 在小鼠人肝细胞癌模型中,DT01联合多柔比星较单用多柔比星显示显著抗肿瘤疗效(p=0.02),且联合组血管化显著减少。

临床应用与阅片要点

  • 作者认为DT01可能通过增强TACE与多柔比星的疗效来增强肝细胞癌治疗。
  • DT01联合TACE在临床前模型中显示显著抗肿瘤疗效且无额外毒性。
  • 在临床前模型中识别出DT01潜在的抗血管生成作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study aimed to explore the antitumour effect of the DNA repair inhibitor, DT01 (the cholesterol conjugated form of Dbait), as an adjunct treatment to enhance the therapeutic efficacy of transarterial chemoembolization (TACE) in pre-clinical models of hepatocellular carcinoma (HCC).

METHODS: A rabbit model bearing liver tumours was either left untreated or treated with TACE or with a combination of TACE+DT01. Tumour growth was monitored by ultrasound. These results were further confirmed in mice grafted with an intrahepatic human HCC model treated with doxorubicin (DOX) alone or DOX+DT01.

RESULTS: The combination of DT01 with TACE in a rabbit liver model led to a significant decrease in tumour volume (p=0.03). Colour Doppler and immunohistochemical staining revealed a strong decrease in vascularization in the DT01+TACE-treated group preventing the tumour growth restart observed after TACE alone. Similarly, the DT01 combination with DOX led to significant anti-tumour efficacy compared to DOX alone (p=0.02) in the human HCC model. In addition, a significant decrease in vascularization in the group receiving combination DT01 and DOX treatment was observed.

CONCLUSIONS: DT01 is well tolerated and may potentiate HCC treatment by enhancing the DNA-damaging and anti-vascularization effect of TACE with doxorubicin.

KEY POINTS: • DT01 combined with TACE leads to significant anti-tumour efficacy without additional toxicity. • A potential anti-angiogenic role of DT01 was identified in preclinical models. • DT01 may potentiate HCC treatment by enhancing the efficacy of TACE.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Herath NI, Devun F, Herbette A, et al. Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models. Eur Radiol. 2017. PMID: 28374075. doi:10.1007/s00330-017-4792-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。